Ascend Wellness Q2 Results: Revenue up 7.9%, EBITDA margin expands
Ascend Wellness Holdings reported Q2 2026 net revenue of $126.1 million, up 7.9% sequentially, driven by an 11.5% rise in retail sales. Adjusted EBITDA reached $29.1 million with a 23.1% margin. The company expanded to 55 retail locations and filed for a reverse stock split to enable a U.S. exchange uplisting.

*this image is generated using AI for illustrative purposes only.
Ascend Wellness Holdings (CSE: AAWH) reported net revenue of $126.1 million for the quarter ended June 30, 2026, representing a 7.9% sequential increase from $116.9 million in the first quarter of 2026. The multi-state cannabis operator also posted an Adjusted EBITDA of $29.1 million, with margins expanding by 60 basis points sequentially to 23.1%.
The financial performance was underpinned by strong growth in the retail channel, which contributed $92.7 million in revenue, up 11.5% sequentially. This growth was primarily driven by expansion in Ohio and incremental contributions from new store openings and partner locations. In contrast, third-party wholesale revenue declined approximately 1% to $33.4 million, reflecting pricing and volume pressures in New Jersey.
Operational Expansion and Market Share
Ascend scaled its retail footprint to 55 locations as of June 30, 2026, up from 48 at the end of the first quarter. Since August 2024, the company has increased its retail presence by approximately 45%. Key operational developments include:
- Opened East Coasting in Eatontown, New Jersey, with four additional partner store opportunities in the New Jersey pipeline.
- Pursuing additional retail licenses in Massachusetts following a regulatory change that raised the per-operator cap from three to six.
- Developing a strategic relationship with an Ohio operator to expand its dispensary network pending regulatory approval.
The company grew its combined market share by approximately 5% sequentially across its seven-state footprint, maintaining its position as the number two brand house by sales and units in Illinois, New Jersey, and Massachusetts.
Financial Metrics and Cash Flow
| Metric | Q2 2026 | Q1 2026 | Sequential Change |
|---|---|---|---|
| Net Revenue | $126.1 million | $116.9 million | +7.9% |
| Retail Revenue | $92.7 million | $83.1 million | +11.5% |
| Wholesale Revenue | $33.4 million | $33.8 million | -1.0% |
| Adjusted Gross Profit Margin | 46.2% | 46.1% | +10 bps |
| Adjusted EBITDA | $29.1 million | $26.3 million | +10.6% |
| Adjusted EBITDA Margin | 23.1% | 22.5% | +60 bps |
Cash and cash equivalents stood at $67.0 million as of June 30, 2026, an increase of $6.1 million sequentially. Net cash provided by operating activities was $22.5 million, resulting in Free Cash Flow of $19.5 million. The company’s Net Debt was $251.8 million.
What the Numbers Show
The divergence between retail and wholesale performance highlights Ascend's strategic shift toward vertical integration. While wholesale revenue contracted due to pricing pressure, retail revenue grew significantly faster than total revenue. This mix shift directly supported the expansion in Adjusted Gross Profit Margin, which rose despite continued wholesale headwinds. The company’s focus on selling its own branded products through its expanding retail network appears to be the primary driver of margin improvement.
Corporate Developments
Ascend filed a definitive proxy statement for a reverse stock split, with a shareholder vote scheduled for August 28, 2026, to facilitate an uplisting to a major U.S. exchange. Additionally, the company submitted applications to the U.S. Drug Enforcement Administration (DEA) to register certain medical cannabis operations under the expedited pathway following the rescheduling of medical cannabis to Schedule III.
For the third quarter of 2026, management anticipates a 2–4% increase in revenue, with Adjusted EBITDA margin expected to remain consistent with Q2 2026 levels.
How will the successful uplisting to a major U.S. exchange impact Ascend's cost of capital and ability to fund its aggressive retail expansion in Ohio and Massachusetts?
What specific operational or pricing strategies is Ascend implementing to reverse the wholesale revenue decline in New Jersey amidst ongoing market saturation?
How might the rescheduling of medical cannabis to Schedule III and subsequent DEA registration alter Ascend's tax liabilities and federal banking access compared to its current Schedule I status?

























